In line with this, Burlot and colleagues demonstrated that bilateral hippocampal injections of AVV-CYP46A1 to THY Tau22 mice, a model of AD-like tau pathology where both CYP46A1 and 24-OHC levels are lower than normal, selectively enhanced CYP46A1 expression and restored 24-OHC levels in hippocampal neurons. This evidence concerns the gene CYP46A1 and Alzheimer disease.